Citations

Clear

3138 citation(s) found for "Smith, AM".

Pilot Evaluation of Bupropion for the Treatment of Hot Flashes
Pérez, Domingo G., Loprinzi, Charles L. , Sloan, Jeff A. , Novotny, Paul J. , Barton, Debra L. , Carpenter, Lisa A., Smith, Deanne, Christensen, Brad, Rummans, Teresa A.

Mayo Clinic

Journal of Palliative Medicine | June 5, 2006 | Volume: 9 | Issue: 3 | Pages: 631-637

10.1089/jpm.2006.9.631 | PMID 16752968 Get It

Severe Respiratory Distress
Naim, Maryam Y. , Schears, Gregory J. , Smith, Ryan J.

Mayo Clinic

Clinical Pediatrics | March 31, 2006 | Volume: 43 | Issue: 4 | Pages: 403-405

10.1177/000992280404300416 | PMID 15118788 Get It

Acute Suppurative Thyroiditis Caused by Pasteurella multocida and Associated with Thyrotoxicosis
McLaughlin, Sarah A. , Meek, Shon , Smith, Stephen L.

Mayo Clinic

Thyroid | March 29, 2006 | Volume: 16 | Issue: 3 | Pages: 307-310

10.1089/thy.2006.16.307 | PMID 16571095 Get It

Dietary Carotenoids and Risk of Lung Cancer in a Pooled Analysis of Seven Cohort Studies
Männistö, Satu , Smith‐Warner, Stephanie A. , Anderson, Kristin E. , Brandt, Piet A. van den , Cerhan, James R. , Colditz, Graham A. , Feskanich, Diane , Freudenheim, Jo L. , Giovannucci, Edward L. , Goldbohm, R. Alexandra, Graham, Saxon, Miller, Anthony B. , Rohan, Thomas E. , Virtamo, Jarmo, Spiegelman, Donna , Albanes, Demetrius , Willett, Walter C. , Hunter, David J. , Cerhan, James R , Colditz, Graham A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 22, 2006 | Volume: 13 | Issue: 1 | Pages: 40-48

10.1158/1055-9965.epi-038-3 | PMID 14744731 Get It

Abstract Intervention trials with supplemental β-carotene have observed either no effect or a harmful effect on lung cancer risk. Because food composition databases for specific carotenoids have only become available recently, epidemiological evidence relating usual dietary levels of these carotenoids with lung cancer risk is limited. We analyzed the association between lung cancer risk and intakes of specific carotenoids using the primary data from seven cohort studies in North America and Europe. Carotenoid intakes were estimated from dietary questionnaires administered at baseline in each study. We calculated study-specific multivariate relative risks (RRs) and combined these using a random-effects model. The multivariate models included smoking history and other potential risk factors. During follow-up of up to 7–16 years across studies, 3,155 incident lung cancer cases were diagnosed among 399,765 participants. β-Carotene intake was not associated with lung cancer risk (pooled multivariate RR = 0.98; 95% confidence interval, 0.87–1.11; highest versus lowest quintile). The RRs for α-carotene, lutein/zeaxanthin, and lycopene were also close to unity. β-Cryptoxanthin intake was inversely associated with lung cancer risk (RR = 0.76; 95% confidence interval, 0.67–0.86; highest versus lowest quintile). These results did not change after adjustment for intakes of vitamin C (with or without supplements), folate (with or without supplements), and other carotenoids and multivitamin use. The associations generally were similar among never, past, or current smokers and by histological type. Although smoking is the strongest risk factor for lung cancer, greater intake of foods high in β-cryptoxanthin, such as citrus fruit, may modestly lower the risk.
Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Karp, Judith E. , Passaniti, Antonino , Gojo, Ivana , Kaufmann, Scott H. , Bible, Keith C. , Garimella, Τushar , Greer, Jacqueline M., Briel, Janet, Gore, Steven D. , Tidwell, Michael L., Ross, Douglas D., Wright, John J., Bauer, Kenneth S., Smith, B. Douglas , Wright, John J., Colevas, Alexander Dimitrios , Kaufmann, Scott H

Mayo Clinic

Clinical Cancer Research | March 21, 2006 | Volume: 11 | Issue: 23 | Pages: 8403-8412

10.1158/1078-0432.ccr-05-1201 | PMID 16322302 Get It

Abstract Purpose: The serine/threonine kinase inhibitor flavopiridol targets multiple cyclin-dependent kinases, induces checkpoint arrest, and interrupts transcriptional elongation. We designed a phase I clinical trial using a timed sequential therapy approach where flavopiridol was given for the dual purpose of initial cytoreduction and enhancing cell cycle progression of the remaining leukemia cell cohort followed by cycle-dependent drugs 1-β-d-arabinofuranosylcytosine (ara-C) and mitoxantrone. Experimental Design: Flavopiridol was given by 1-hour infusion daily for 3 days beginning day 1 followed by 2 g/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone beginning day 9. In vivo correlates included pharmacokinetics, modulation of blast cycle regulators, and serum and marrow supernatant vascular endothelial growth factor levels. Results: Of 34 adults receiving induction therapy, 16 (47%) evinced direct leukemia cytotoxicity with ≥50% drop in peripheral blast counts and tumor lysis in 9 (26%). Four (12%) died during therapy (two fungal infections and two sudden death). Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia >40 days duration, and maximal tolerated dose was 50 mg/m2/d. Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia. Pharmacokinetics showed that a linear two-compartment model with first-order elimination provided the best fit of the observed concentration versus time data. Flavopiridol down-regulated one or more target proteins in marrow blasts in vivo. Vascular endothelial growth factor was detected in sera and marrow supernatant pretreatment, and sera obtained on day 3 inhibited bovine aortic endothelial cell proliferation by a mean of 32% (range, 10-80%). Conclusions: Our data suggest that flavopiridol is cytotoxic to leukemic cells and, when followed by ara-C and mitoxantrone, exerts biological and clinical effects in patients with relapsed and refractory acute leukemias. These findings warrant continuing development of flavopiridol at 50 mg/m2/d × 3 days in combination with cytotoxic and biological agents for acute leukemias.
Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo
Crawford, E. David , Wilson, Shandra, McConnell, John D., Slawin, Kevin M., Lieber, Michael C., Smith, Joseph A. , Meehan, Alan G., Bautista, Oliver, Noble, William R., Kusek, John W., Nyberg, Leroy M., Roehrborn, Claus G.

Mayo Clinic

Journal of Urology | March 3, 2006 | Volume: 175 | Issue: 4 | Pages: 1422-1427

10.1016/s0022-5347(05)00708-1 | PMID 16516013 Get It

Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates
Gordon, Kristine A., Toki, Brian E., Yamane, Andrew K., Hering, Michelle A., Cerveny, Charles G., Petroziello, Joseph M., Ryan, Maureen C. , Smith, Leia M., Simon, Ronald , Sauter, Guido , Oflazoglu, Ezogelin, Doronina, Svetlana O., Meyer, Damon L., Francisco, Joseph A., Senter, Peter D. , Copland, John A. , Wood, Christopher G. , Wahl, Alan F., Law, Che‐Leung , Carter, Paul

Mayo Clinic

Cancer Research | February 17, 2006 | Volume: 66 | Issue: 4 | Pages: 2328-2337

10.1158/0008-5472.can-05-2883 | PMID 16489038 Get It

AbstractMetastatic renal cell carcinoma (RCC) is an aggressive disease refractory to most existing therapeutic modalities. Identifying new markers for disease progression and drug targets for RCC will benefit this unmet medical need. We report a subset of clear cell and papillary cell RCC aberrantly expressing the lymphocyte activation marker CD70, a member of the tumor necrosis factor superfamily. Importantly, CD70 expression was found to be maintained at the metastatic sites of RCC. Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives of the anti-tubulin agent auristatin, mediated potent antigen-dependent cytotoxicity in CD70-expressing RCC cells. Cytotoxic activity of these anti-CD70 ADCs was associated with their internalization and subcellular trafficking through the endosomal-lysosomal pathway, disruption of cellular microtubule network, and G2-M phase cell cycle arrest. The efficiency of drug delivery using anti-CD70 as vehicle was illustrated by the much enhanced cytotoxicity of antibody-conjugated MMAF compared with free MMAF. Hence, ADCs targeted to CD70 can selectively recognize RCC, internalize, and reach the appropriate subcellular compartment(s) for drug release and tumor cell killing. In vitro cytotoxicity of these ADCs was confirmed in xenograft models using RCC cell lines. Our findings provide evidence that CD70 is an attractive target for antibody-based therapeutics against metastatic RCC and suggest that anti-CD70 ADCs can provide a new treatment approach for advanced RCC patients who currently have no chemotherapeutic options. (Cancer Res 2006; 66(4): 2328-37)
The Detection of Human Papillomavirus Deoxyribonucleic Acid in Intraepithelial, in Situ, Verrucous and Invasive Carcinoma of the Penis
Cupp, Michael R., Malek, Reza S., Goellner, John R., Smith, Thomas F., Espy, Mark J.

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 154 | Issue: 3 | Pages: 1024-1029

10.1016/s0022-5347(01)66967-2 Get It

Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing
Espy, Mark J., Uhl, J. R., Sloan, Lynne M., Buckwalter, Seanne P., Jones, Mary F. , Vetter, Emily A., Yao, Joseph D. , Wengenack, Nancy L. , Rosenblatt, Jon E., Cockerill, Franklin R., Smith, Thomas F.

Mayo Clinic

Clinical Microbiology Reviews | January 17, 2006 | Volume: 19 | Issue: 1 | Pages: 165-256

10.1128/cmr.19.1.165-256.2006 | PMID 16418529 Get It

SUMMARY Real-time PCR has revolutionized the way clinical microbiology laboratories diagnose many human microbial infections. This testing method combines PCR chemistry with fluorescent probe detection of amplified product in the same reaction vessel. In general, both PCR and amplified product detection are completed in an hour or less, which is considerably faster than conventional PCR detection methods. Real-time PCR assays provide sensitivity and specificity equivalent to that of conventional PCR combined with Southern blot analysis, and since amplification and detection steps are performed in the same closed vessel, the risk of releasing amplified nucleic acids into the environment is negligible. The combination of excellent sensitivity and specificity, low contamination risk, and speed has made real-time PCR technology an appealing alternative to culture- or immunoassay-based testing methods for diagnosing many infectious diseases. This review focuses on the application of real-time PCR in the clinical microbiology laboratory.
Arthroscopic Shoulder Synovectomy in Patients With Rheumatoid Arthritis
Sperling, John W. , O’Driscoll, Shawn W. , Cofield, Robert H. , Smith, Adam , Fitzsimmons, James S

Mayo Clinic

Arthroscopy | January 8, 2006 | Volume: 22 | Issue: 1 | Pages: 50-56

10.1016/j.arthro.2005.10.011 | PMID 16399461 Get It

Purpose Currently, there is little information available concerning the results of shoulder synovectomy in patients with rheumatoid arthritis. Furthermore, it remains difficult to assess the success of shoulder synovectomy because of a high association of rotator cuff tears in rheumatoid patients. We hypothesized that synovectomy in patients with a functionally intact rotator cuff would provide durable pain relief. Type of Study Case series. Methods Sixteen shoulders in 13 patients with rheumatoid arthritis were treated with arthroscopic shoulder synovectomy from 1988 to 2002 with a mean follow‐up of 5.5 years. Patients with full‐thickness rotator cuff tears or partial tears that required repair were excluded. Two of the 13 patients had been diagnosed with juvenile rheumatoid arthritis and 11 had adult‐onset disease. The medical records of the patients were reviewed and patients were assessed clinically and by questionnaire to assess pain, satisfaction, range of motion, radiographic outcomes, and occurrence of complications. Results There was an improvement in pain at long‐term follow‐up in 13 of 16 patients ( P < .001). Active shoulder elevation improved from a median of 145° to 160° but was not significant ( P = .14). External rotation improved significantly ( P = .01) from a median of 45° (range, 0° to 90°) to 60° (range, 0° to 100°). According to the Neer rating system, there were 5 excellent, 8 satisfactory, and 3 unsatisfactory results. Seven of 8 shoulders followed‐up radiographically for more than 1 year showed radiographic progression of disease. All 3 patients reporting pain that was no better or worse than before surgery had radiographic arthrosis at last follow‐up with advancing periarticular erosions and reduction of glenoid articular space. Conclusions Arthroscopic synovectomy of the shoulder in patients with rheumatoid arthritis with an intact rotator cuff offers a reliable decrease in pain with less predictable improvements in range of motion. Limitations in predicting final results based on preoperative radiographs should be discussed with patients; those with more advanced radiographic changes may not benefit from the procedure. Level of Evidence Level IV, therapeutic study, case series, no control group.